Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Safety and Clinical Efficacy of AZVUDINE in COVID-19 Patients (SARS-CoV-2 Infected): Phase III, Randomized, Double-blind, PLACEBO Controlled Trial

NCT04668235 is registered in ClinicalTrials.gov with HRH Pharmaceuticals Limited as lead sponsor.

NCT NCT04668235
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04668235 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Safety and Clinical Efficacy of AZVUDINE in COVID-19 Patients (SARS-CoV-2 Infected): Phase III, Randomized, Double-blind, PLACEBO Controlled Trial
Lead sponsor
HRH Pharmaceuticals Limited
Phase
Phase 3
Overall status
Completed
Start date
April 23, 2021
Completion date
August 10, 2022
Enrollment
180 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19